Literature DB >> 21423259

IBD: Adalimumab for ulcerative colitis— is the glass half empty or half full?

Alessandro Armuzzi1, Daniela Pugliese.   

Abstract

Antibodies that target tumor necrosis factor are effective at inducing and maintaining remission in both Crohn's disease (infliximab, adalimumab and certolizumab) and ulcerative colitis (infliximab). The results of a randomized controlled trial of adalimumab for inducing remission in moderately to severely active ulcerative colitis have now been published.

Entities:  

Year:  2011        PMID： 21423259     DOI： 10.1038/nrgastro.2011.48

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

1.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

2.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

3.  A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.

Authors:  Abderrahim Oussalah; Ludovic Evesque; David Laharie; Xavier Roblin; Gilles Boschetti; Stéphane Nancey; Jérôme Filippi; Bernard Flourié; Xavier Hebuterne; Marc-André Bigard; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2010-08-24       Impact factor: 10.864

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

Review 5.  Adalimumab in ulcerative colitis: hypes and hopes.

Authors:  Gionata Fiorino; Laurent Peyrin-Biroulet; Alessandro Repici; Alberto Malesci; Silvio Danese
Journal:  Expert Opin Biol Ther       Date:  2011-01       Impact factor: 4.388

6.  Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.

Authors:  Alan Menter; Kenneth B Gordon; Craig L Leonardi; Yihua Gu; Orin M Goldblum
Journal:  J Am Acad Dermatol       Date:  2010-06-03       Impact factor: 11.527

7.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

8.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.

Authors:  William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2009-07-28       Impact factor: 22.682

9.  Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Authors:  Michael H Weisman; Larry W Moreland; Daniel E Furst; Michael E Weinblatt; Edward C Keystone; Harold E Paulus; Leah S Teoh; Raja B Velagapudi; Peter A Noertersheuser; G Richard Granneman; Steven A Fischkoff; Elliot K Chartash
Journal:  Clin Ther       Date:  2003-06       Impact factor: 3.393

10.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682
  10 in total
  1 in total

1.  A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.

Authors:  Norfilza Mohd Mokhtar; Khairul Najmi Muhammad Nawawi; Jaarvis Verasingam; Wong Zhiqin; Ismail Sagap; Zairul Azwan Mohd Azman; Luqman Mazlan; Hamzaini Abdul Hamid; Nur Yazmin Yaacob; Isa Mohamed Rose; Eden Low Ngah Den; Mah Suit Wan; Raja Affendi Raja Ali
Journal:  BMC Public Health       Date:  2019-06-13       Impact factor: 3.295
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.